Plan ahead of these events, and schedule time with us!
We can help you:
Events Beacon will be attending
2nd Annual TIGIT Therapies Summit 2021
December 7-9, 2021, Digital Event
The 2nd Annual TIGIT Therapies Summit remains the only dedicated forum gathering biopharma drug developers to discuss this next-generation checkpoint inhibitor to advance clinical progress and deliver to those patients most in need.
This event will allow you to address the key challenges associated with TIGIT therapy development and propel TIGIT to clinical use.Register Here
DDR, ATR & PARP Inhibitors Summit 2022
January 25-27, 2022 Boston, MA
The 5th Annual PARP, ATR & DDR Inhibitors Summit is the one-of-a-kind industry-focused summit dedicated to bringing new and novel next-generation DDR therapeutics to the clinic and finding optimal treatment combinations to expand application in multiple cancer indications.
This is the key in-person biopharma conference for any research team developing inhibitors of specific DDR targets, in either monotherapy or in combination, to treat predictable, identifiable, DDR-defective cancer indicationsRegister Here
LAG-3 Targeted Drug Development Summit 2022
January 25-27, 2022 | Digital Event
With the recent clinical validation by BMS, LAG-3 combinations are spearheading the next wave of immune checkpoint inhibitors. As such, there has been an explosion of interest and high-scale investment into this exciting space.
Arriving at a critical point for LAG-3 development, the first ever LAG-3 Targeted Drug Development Summit is the definitive industry-led event focused on propelling this next generation inhibitor to clinical use.
Here’s what you can look forward to:
- Get clinical updates on current bispecific antibody approaches from Laura Codari Deak (Roche Innovation Center), Michelle Morrow (F-Star Biotechnology) and Paul Moore (Macrogenics)
- Take a look at the potential of LAG-3 in haematological cancers with Segundo Rodriguez (Universidad de Oviedo)
- Explore the mechanism of action and understand how LAG-3 mediates its inhibitory function with Creg Workman (University of Pittsburgh)
- Understand how LAG-3 acts in non-oncological conditions with our interactive online workshop with Jon Piganelli (University of Pittsburgh)
Due to the impacts of COVID-19, we will be monitoring the activities of key conferences, to find out more about how we monitor this, please view our conference tracker.